Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05848128 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
A Phase 3 study, sponsored by Mimetogen Pharmaceuticals USA.
- Completed
- Registry status
- Phase 3
- Development phase
- 642
- Enrollment target
NCT05848128 is a Phase 3 study that has completed, run by Mimetogen Pharmaceuticals USA. The registered enrollment target is 642 participants.
The verdict
NCT05848128, a Phase 3 study, has completed, sponsored by Mimetogen Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 642 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the efficacy and safety of 5% tavilermide ophthalmic solution to placebo for the treatment of the signs and symptoms of dry eye disease.
Interventions
- OTHER Vehicle ophthalmic solution
- DRUG 5% Tavilermide ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 642 participants |
| Start Date | 2023-06-28 |
| Est. Completion | 2024-05-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05848128
The ClinicalTrials.gov registry entry for NCT05848128 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 642 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mimetogen Pharmaceuticals USA, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle ophthalmic solution is the first listed.
NCT05848128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05848128 about?
NCT05848128 is a clinical study titled "Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye". The purpose of the study is to compare the efficacy and safety of 5% tavilermide ophthalmic solution to placebo for the treatment of the signs and symptoms of dry eye disease.
What is the current status of trial NCT05848128?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 642 participants. The study started on 2023-06-28. Estimated completion is 2024-05-11.
What interventions are being tested in trial NCT05848128?
The interventions under investigation include: Vehicle ophthalmic solution (OTHER), 5% Tavilermide ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT05848128?
This trial is sponsored by Mimetogen Pharmaceuticals USA, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.